HI
CYTK icon

Harbour Investments’s Cytokinetics CYTK Stock Holding History

Harbour Investments’s Portfolio CYTK Stock Details CYTK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.04K Buy
24
+12
+100% +$862 ﹤0.01% 4016
2026
Q1 		$791 Buy
12
+10
+500% +$636 ﹤0.01% 4161
2025
Q4 		$127 Buy
+2
New +$124 ﹤0.01% 3721

Other funds holding CYTK

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $11.1B AUM 207.82% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Harbour Investments's CYTK Position: Q2 2026 in Review

Harbour Investments increased its Cytokinetics (CYTK) stake by 100% in Q2 2026, buying an estimated $862 and bringing the position to 24 shares worth $2.04K. The position accounts for ﹤0.01% of the portfolio, ranked #4016.

Harbour Investments first reported a position in CYTK in Q4 2025 and has held it in 3 quarters since. 482 funds tracked by Wall St. Rank hold CYTK as of Q2 2026.

  • Harbour Investments held 24 shares of Cytokinetics worth $2.04K as of Q2 2026.
  • Harbour Investments bought 12 Cytokinetics shares in Q2 2026, an estimated $862.
  • Cytokinetics made up ﹤0.01% of Harbour Investments's portfolio in Q2 2026, its #4016 holding.
  • Harbour Investments first reported a position in Cytokinetics in Q4 2025 and has held it in 3 quarters since.
  • 482 funds tracked by Wall St. Rank held Cytokinetics as of Q2 2026.

Based on Harbour Investments's 13F filing for Q2 2026, filed 12 Aug 2026.